Andere Sprachen Teva Pharmaceutical Industries Limited TEL AVIV STOCK EXCHANGE

Aktien

906517

IL0006290147

TEVA

Markt geschlossen - TEL AVIV STOCK EXCHANGE Andere Börsenplätze 16:24:19 06.05.2024			% 5 Tage	% 1. Jan.
5 207 ^ILa	+1,19 %		-1,23 %	+36,49 %

01.05.	HINTERGRUND/FTC knöpft sich Patentanmeldungen für Arzneimittel vor	DJ
30.04.	FTC beanstandet 'Junk'-Patentlisten für Ozempic, Victoza und andere Medikamente	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Teva's 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets	03.05.
Teva to Present at the 2024 Bank of America Healthcare Conference	03.05.
Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets	02.05.
Alvotech - U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-FreeInterchangeable Biosimilar to Humira	01.05.
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	30.04.
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings	30.04.
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	30.04.
Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals	30.04.
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	30.04.
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	30.04.
Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent	30.04.
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)	30.04.
Vanda Pharmaceuticals Appeal for Patents on Sleep Drug Declined by US Supreme Court	22.04.
Alvotech Shares Rise After Signing Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US	19.04.
Alvotech Signs Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US	19.04.
Teva's New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO Tablets	17.04.
Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)	17.04.
Alvotech, Teva Win US FDA Approval for Selarsdi Injection to Treat Severe Plaque Psoriasis, Psoriatic Arthritis	16.04.
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)	16.04.
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)	16.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Schlagzeilen

Teva Pharmaceutical Industries Limited: Muss weiter Federn lassen

Am 01. Februar 2024 um 11:04 Uhr

Teva CEO über das zweite Quartal und einen möglichen DOJ-Vergleich

Am 02. August 2023 um 21:19 Uhr